Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term study of N-Acetyl-GED-0507-34-Levo gel in acne vulgaris
2023-510342-24-00Phase 3Authorised
- Sponsor
- PPM Services
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of N-acetyl-GED-0507-34-LEVO in acne vulgaris, sponsored by PPM Services. Primary endpoints: Incidence of adverse events, Treatment discontinuation due to TEAEs and 5 more. Planned start Nov 2024; status: authorised.
02
Drugs
N-acetyl-GED-0507-34-LEVO
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2023-510342-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510342-24-00.